A Phase 2 interventional study of Infanrix Hexa in Acellular Pertussis, Diphtheria and Poliomyelitis, sponsored by GlaxoSmithKline. Completed at 6 sites in Finland. Open to participants aged 16 Months to 20 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Diphtheria.
Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria, this one is the 10th largest by enrollment, is one of 3 that started in 2008, is one of 2 in phase 2, and was the 5th registered.
268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.
Browse Diphtheria studies →None of the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria is open now. The open studies under Diphtheria, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.
This study: 16 Months to 20 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2008.
This study's enrollment of 403 is below the median of 449 across 242 interventional studies indexed under Diphtheria.
Median enrollment 494 across the 15 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
101 studies in Diphtheria by GlaxoSmithKline: none open now, 1 under way, 1 of them phase 3. Of 99 finished, 59 (60%) have results posted.
Among the 101 studies in Diphtheria by GlaxoSmithKline, this one is the 53rd largest by enrollment of the 92 interventional ones that give a count, is one of 6 that started in 2008, is one of 15 in phase 2, and was the 43rd registered.
GlaxoSmithKline’s Diphtheria studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 101 in Diphtheria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this booster study is to evaluate, in subjects primed in the primary study 106786, the persistence, at the time of the booster vaccination, of antibodies elicited by the different formulation of DTPa-HBV-IPV/ Hib vaccine (Infanrix Hexa TM). The study will also evaluate the immune response of these subjects to a DTPa-HBV-IPV/Hib booster. This protocol posting deals with the objectives and outcome measures of the booster phase. The objectives and outcomes measures of the primary phase are presented in a separate protocol posting (NCT = 00376779).
This protocol posting has been updated in order to comply with the FDA AA, Sep 2007.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
Biological: Infanrix Hexa
Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
Biological: Infanrix Hexa
Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
Biological: Infanrix Hexa
Vaccine administered as a booster dose at 16-20 months of age
Also known as: GSK Biological's combined DTPa-HBV-IPV/Hib vaccine
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
Time frame: Before the booster administration (At Month 0)
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL). Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
Time frame: Before the booster vaccination (At Month 0)
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3
A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.
Time frame: Before the booster vaccination (At Month 0)
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3
A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: Before the booster vaccination (At Month 0)
Number of Seroprotected Subjects Against Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg/mL). Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Time frame: Before the booster vaccination (At Month 0)
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Subjects With a Vaccine Response to PT, FHA and PR
Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) \[i.e. with concentrations lower than (\<) the cut-off value\] or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) \[i.e. with concentrations greater than (\>) the cut-off value).
Time frame: One month after the booster vaccination (At Month 1)
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
Time frame: Before the booster vaccination (At Month 0)
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
Time frame: One month after the booster vaccination (At Month 1)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Time frame: Before the booster vaccination (At Month 0)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Time frame: One month after the booster vaccination (At Month 1)
Anti-HBs Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Time frame: Before the booster vaccination (At Month 0)
Anti-HBs Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Time frame: One month after the booster vaccination (At Month 1)
Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs).
Time frame: Before the booster vaccination (At Month 0)
Anti-poliovirus Type 1, Type 2 and Type 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs).
Time frame: One month after the booster vaccination (At Month 1)
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in micrograms per milliliter (µg/mL).
Time frame: Before the booster vaccination (At Month 0)
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
Time frame: One month after the booster vaccination (At Month 1)
Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL .
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Number of Seroprotected Subjects Against Poliovirus Type 1, Type 2 and Type 3
A seroprotected subject was defined as a subject with anti-polio 1, 2 and 3 antibody titers ≥ the value of 8.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Number of Seroprotected Subjects Against PT, FHA and PRN
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL .
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP)
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 μg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Anti-HBs Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Anti-poliovirus Type 1, 2 and 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs).
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
Time frame: Before (Month 0) and one month after (Month 1) the booster vaccination
Number of Subjects With a Vaccine Response to PT, FHA and PR
Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) (i.e. with concentrations \< cut-off value) or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) (i.e. with concentrations \> cut-off value).
Time frame: One month after the booster dose (At Month 1)
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination
Number of Subjects With Any Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above (≥) 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Day 0-30) follow-up period after the booster vaccination
Number of Subjects With Serious Adverse Events (SAEs)
Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 0 to Month 1, during the entire study period
Number of Subjects Reporting Concomitant Medications
Time frame: During the 4-day (Days 0-3) follow-up period after the booster vaccination
| Milestone | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Started | 127 | 137 | 139 |
| Completed | 123 | 130 | 133 |
| Not completed | 4 | 7 | 6 |
| Withdrew: Migrated from study area | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 6 | 5 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 |
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-D | 22 | 35 |
| Anti-T | 93 | 103 |
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations greater than or equal to (≥) 0.1 IU/mL.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-D | 112 | 118 |
| Anti-T | 113 | 118 |
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL). Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-HBs ≥ 10 mIU/mL | 106 | 112 |
| Anti HBs ≥ 100 mIU/mL | 55 | 54 |
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-HBs ≥ 10 mIU/mL | 110 | 117 |
| Anti HBs ≥ 100 mIU/mL | 105 | 113 |
A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-polio 1 | 67 | 76 |
| Anti-polio 2 | 48 | 51 |
| Anti-polio 3 | 58 | 77 |
A seroprotected subject was defined as a subject with anti-Polio 1, 2 and 3 antibody titers ≥ the value of 8.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-polio 1 | 110 | 117 |
| Anti-polio 2 | 110 | 117 |
| Anti-polio 3 | 111 | 117 |
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PT | 80 | 81 |
| Anti-FHA | 106 | 107 |
| Anti-PRN | 81 | 86 |
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PT | 111 | 118 |
| Anti-FHA | 112 | 118 |
| Anti-PRN | 113 | 117 |
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations greater than or equal to (≥) 0.15 micrograms per milliliter (µg/mL). Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PRP ≥ 0.15μg/mL | 71 | 87 |
| Anti-PRP ≥ 1.0μg/mL | 15 | 23 |
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 µg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PRP ≥ 0.15 µg/mL | 112 | 119 |
| Anti-PRP ≥ 1.0 µg/mL | 111 | 117 |
Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) \[i.e. with concentrations lower than (\<) the cut-off value\] or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) \[i.e. with concentrations greater than (\>) the cut-off value).
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PT, S- | 29 | 30 |
| Anti-PT, S+ | 78 | 81 |
| Anti-PT, Total | 107 | 111 |
| Anti-FHA, S- | 4 | 4 |
| Anti-FHA, S+ | 104 | 106 |
| Anti-FHA, Total | 108 | 110 |
| Anti-PRN, S- | 31 | 30 |
| Anti-PRN, S+ | 81 | 85 |
| Anti-PRN, Total | 112 | 115 |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
| IU/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-D | 0.064 (0.058 to 0.071) | 0.069 (0.062 to 0.076) |
| Anti-T | 0.216 (0.184 to 0.254) | 0.248 (0.213 to 0.289) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
| IU/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-D | 2.237 (1.877 to 2.666) | 2.242 (1.868 to 2.689) |
| Anti-T | 9.799 (8.39 to 11.444) | 9.136 (7.838 to 10.648) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
| EL.U/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PT | 7.8 (6.7 to 9.1) | 7 (6.1 to 8.1) |
| Anti-FHA | 21.7 (18.1 to 25.9) | 22.1 (18.5 to 26.2) |
| Anti-PRN | 8.6 (7.1 to 10.3) | 8.7 (7.3 to 10.2) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
| EL.U/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PT | 150.9 (132.9 to 171.2) | 117.1 (101.5 to 135) |
| Anti-FHA | 609.6 (534.1 to 695.7) | 533.7 (463 to 615.1) |
| Anti-PRN | 308.5 (261.3 to 364.2) | 311.7 (260.3 to 373.2) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
| mIU/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-HBs Antibody Concentrations | 84.3 (65.7 to 108.2) | 86.2 (67.8 to 109.6) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
| mIU/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-HBs Antibody Concentrations | 3291.7 (2373.6 to 4565) | 3528.1 (2546.1 to 4888.9) |
Antibody titers were presented as geometric mean titers (GMTs).
| Titers | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-polio 1 | 12.9 (10.3 to 16.3) | 15.2 (12.3 to 18.9) |
| Anti-polio 2 | 9.1 (7.3 to 11.3) | 8.7 (7.2 to 10.5) |
| Anti-polio 3 | 9.5 (7.9 to 11.6) | 16 (12.6 to 20.4) |
Antibody titers were presented as geometric mean titers (GMTs).
| Titers | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-polio 1 | 726.3 (560.4 to 941.4) | 942.4 (734.1 to 1209.7) |
| Anti-polio 2 | 712.8 (529.1 to 960.4) | 812.9 (632.8 to 1044.3) |
| Anti-polio 3 | 780 (591 to 1029.3) | 1145.8 (891.6 to 1472.5) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in micrograms per milliliter (µg/mL).
| µg/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PRP Antibody Concentrations | 0.249 (0.199 to 0.31) | 0.314 (0.252 to 0.392) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
| µg/mL | Infanrix Hexa PF Group | Infanrix Hexa PC Group |
|---|---|---|
| Anti-PRP Antibody Concentrations | 36.866 (28.61 to 47.504) | 35.318 (27.447 to 45.445) |
A seroprotected subject was defined as a subject with anti-D and anti-T antibody concentrations ≥ 0.1 IU/mL .
| Participants | Control Group |
|---|---|
| Anti-D, M0 | 40 |
| Anti-D, M1 | 119 |
| Anti-T, M0 | 95 |
| Anti-T, M1 | 119 |
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL. Also reported are the number of participants with anti-HBs antibody concentrations ≥ 100 mIU/mL.
| Participants | Control Group |
|---|---|
| Anti-HBs ≥ 10 mIU/mL, M0 | 106 |
| Anti-HBs ≥ 10 mIU/mL, M1 | 118 |
| Anti HBs ≥ 100 mIU/mL, M0 | 67 |
| Anti HBs ≥ 100 mIU/mL, M1 | 114 |
A seroprotected subject was defined as a subject with anti-polio 1, 2 and 3 antibody titers ≥ the value of 8.
| Participants | Control Group |
|---|---|
| Anti-polio 1, M0 | 84 |
| Anti-polio 1, M1 | 112 |
| Anti-polio 2, M0 | 56 |
| Anti-polio 2, M1 | 112 |
| Anti-polio 3, M0 | 82 |
| Anti-polio 3, M1 | 113 |
A seroprotected subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL .
| Participants | Control Group |
|---|---|
| Anti-PT, M0 | 93 |
| Anti-PT, M1 | 119 |
| Anti-FHA, M0 | 109 |
| Anti-FHA, M1 | 119 |
| Anti-PRN, M0 | 99 |
| Anti-PRN, M1 | 119 |
A seroprotected subject was defined as a subject with anti-PRP antibody concentrations ≥ 0.15 μg/mL. Also reported are the number of participants with anti-PRP antibody concentrations ≥ 1.0 µg/mL.
| Participants | Control Group |
|---|---|
| Anti-PRP ≥ 0.15 μg/mL, M0 | 92 |
| Anti-PRP ≥ 0.15 μg/mL, M1 | 119 |
| Anti-PRP ≥ 1.0 μg/mL, M0 | 32 |
| Anti-PRP ≥ 1.0 μg/mL, M1 | 118 |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in IU/mL.
| IU/mL | Control Group |
|---|---|
| Anti-D, M0 | 0.084 (0.073 to 0.097) |
| Anti-D, M1 | 3.952 (3.365 to 4.642) |
| Anti-T, M0 | 0.261 (0.219 to 0.31) |
| Anti-T, M1 | 10.833 (9.505 to 12.347) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
| EL.U/mL | Control Group |
|---|---|
| Anti-PT, M0 | 8.9 (7.7 to 10.3) |
| Anti-PT, M1 | 153.7 (135.1 to 174.9) |
| Anti-FHA, M0 | 33.7 (27.6 to 41.1) |
| Anti-FHA, M1 | 791.9 (708.8 to 884.8) |
| Anti-PRN, M0 | 15.3 (12.6 to 18.5) |
| Anti-PRN, M1 | 564.1 (489.5 to 650.1) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
| mIU/mL | Control Group |
|---|---|
| Anti-HBs, M0 | 139.8 (107.2 to 182.3) |
| Anti-HBs, M1 | 6132.7 (4587.8 to 8197.9) |
Antibody titers were presented as geometric mean titers (GMTs).
| Titers | Control Group |
|---|---|
| Anti-polio 1, M0 | 21.6 (17.1 to 27.4) |
| Anti-polio 1, M1 | 1288.8 (1029.1 to 1614) |
| Anti-polio 2, M0 | 11.8 (9.2 to 15) |
| Anti-polio 2, M1 | 1231 (961 to 1576.9) |
| Anti-polio 3, M0 | 21.3 (16.4 to 27.7) |
| Anti-polio 3, M1 | 1794.8 (1426.8 to 2257.7) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
| µg/mL | Control Group |
|---|---|
| Anti-PRP, M0 | 0.487 (0.383 to 0.62) |
| Anti-PRP, M1 | 77.087 (60.224 to 98.672) |
Vaccine response was defined as the appearance of antibodies in subjects who were initially seronegative (S-) (i.e. with concentrations \< cut-off value) or at least doubling of pre-vaccination antibody concentrations in subjects who were initially seropositive (S+) (i.e. with concentrations \> cut-off value).
| Participants | Control Group |
|---|---|
| Anti-PT, S- | 17 |
| Anti-PT, S+ | 93 |
| Anti-PT, Total | 110 |
| Anti-FHA, S- | 0 |
| Anti-FHA, S+ | 105 |
| Anti-FHA, Total | 105 |
| Anti-PRN, S- | 12 |
| Anti-PRN, S+ | 98 |
| Anti-PRN, Total | 110 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Any Pain | 74 | 76 | 82 |
| Any Redness | 66 | 79 | 94 |
| Any Swelling | 44 | 53 | 60 |
Assessed solicited general symptoms were drowsiness, fever \[defined as rectal temperature equal to or above (≥) 38.0 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Any Drowsiness | 50 | 48 | 58 |
| Any Fever (Rectal) | 22 | 34 | 31 |
| Any Irritability | 68 | 86 | 78 |
| Any Loss of Appetite | 37 | 46 | 45 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 51 | 54 | 61 |
Assessed SAEs include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 1 | 2 | 1 |
| Participants | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Any concomitant medication | 105 | 111 | 116 |
| Any antipyretic | 34 | 35 | 33 |
Collected over Solicited symptoms: during the 4-day (Days 0-3) period after the booster vaccination. Unsolicited AEs: during the 31-day (Days 0-30) period after the booster vaccination. SAEs: during the entire study period (from Month 0 up to Month 1).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix Hexa PF Group | 0/127 (0%) | 1/127 (0.8%) | 116/127 (91.3%) |
| Infanrix Hexa PC Group | 0/137 (0%) | 2/137 (1.5%) | 126/137 (92%) |
| Control Group | 0/139 (0%) | 1/139 (0.7%) | 129/139 (92.8%) |
| Event | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| Gastroenteritis rotavirusInfections and infestations | 1/127 | 1/137 | 0/139 |
| GastroenteritisInfections and infestations | 0/127 | 1/137 | 0/139 |
| Pneumonia adenoviralInfections and infestations | 0/127 | 0/137 | 1/139 |
| Event | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group |
|---|---|---|---|
| RednessGeneral disorders | 66/126 | 79/136 | 94/138 |
| IrritabilityGeneral disorders | 68/126 | 86/136 | 78/138 |
| PainGeneral disorders | 74/126 | 76/136 | 82/138 |
| SwellingGeneral disorders | 44/126 | 53/136 | 60/138 |
| DrowsinessGeneral disorders | 50/126 | 48/136 | 58/138 |
| Loss of appetiteGeneral disorders | 37/126 | 46/136 | 45/138 |
| Fever/(Rectal)General disorders | 22/126 | 34/136 | 31/138 |
| Otitis mediaInfections and infestations | 4/127 | 7/137 | 14/139 |
| Injection site indurationGeneral disorders | 5/127 | 2/137 | 10/139 |
| Upper respiratory tract infectionInfections and infestations | 9/127 | 8/137 | 6/139 |
| Age, Continuous(Months) | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group | Total |
|---|---|---|---|---|
| Mean | 17.9 ± 1.12 | 18 ± 1.03 | 17.8 ± 1.11 | 17.90 ± 1.09 |
| Sex: Female, Male(Participants) | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group | Total |
|---|---|---|---|---|
| Female | 56 | 66 | 59 | 181 |
| Male | 71 | 71 | 80 | 222 |
| Race/Ethnicity, Customized(Participants) | Infanrix Hexa PF Group | Infanrix Hexa PC Group | Control Group | Total |
|---|---|---|---|---|
| Geographic ancestry — White-Caucasian/European heritage | 125 | 134 | 135 | 394 |
| Geographic ancestry — White-Arabic/North African heritage | 0 | 1 | 1 | 2 |
| Geographic ancestry — Not specified | 2 | 2 | 3 | 7 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Feb 2008, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2017, 8 years 10 months after primary completion. A results delay was requested in May 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine